Archive for category: Media coverage

Pharma has invested heavily in bringing therapy closer to patients. But from the vantage point of the pharmacy counter, something critical is missing. Pleio’s Chief Pharmacy Officer Mark Gregory writes for MM&M on the emotional barriers DTP programs consistently overlook, and what it takes to build patient support that actually works. Mark makes the case that as DTP models expand and the medication journey becomes increasingly decentralized, pharmacist insight into how patients experience and discontinue therapy should shape program design from the start.

In part two of his Pharmaceutical Commerce interview series, Pleio CEO Michael Oleksiw reframes pharma’s adherence problem as fundamentally human — not logistical. From the industry’s persistent “one-and-done” challenge to the underestimated role of loneliness in early discontinuation, Oleksiw makes the case that lasting behavior change requires meeting patients emotionally before overwhelming them with tools, reminders, or information they aren’t yet ready to act on.

In part one of his two-part Pharmaceutical Commerce interview series, Pleio CEO Michael Oleksiw unpacks the hidden barriers to adherence that legacy patient support programs were never built to detect — and makes the case that AI-powered insights are now giving pharma companies a clearer, faster window into why patients actually stop. With oral GLP-1 therapies reshaping the market, the cost of not knowing is growing.

Pleio’s Chief Experience Officer Abby Reynolds, PharmD, joined First Report Managed Care to discuss how emotional readiness shapes outcomes in specialty drug management — and why even clinically appropriate therapies stall when patients aren’t supported before functional demands peak.

Pleio’s Chief Pharmacy Officer Mark Gregory, RPh discusses how oral GLP-1 medication will impact the patient medication journey, highlighting how easier access may improve initiation but not necessarily adherence. He explores how fragmented support, knowledge gaps, and emotional barriers can undermine persistence, and why sustained outcomes will depend on coordinated guidance beyond the prescription.